Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 27;102(11):1833–1841. doi: 10.3324/haematol.2015.136671

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 3. — The ADAMTS13^1239–1253 peptide is an immunodominant T-cell epitope for HLA-DRB1*11 individuals. CD4⁺ T-cell lines from HLA-DRB1*11 TTP patients at (A) acute phase or (B) in remission phase of the disease, or from (C) a HLA-DRB1*11 healthy donor, were stimulated with the ADAMTS13-derived peptides identified as immunodominant for HLA-DRB1*01. T cells (3×10⁵ cells/well) were incubated with AAPC^DR11 (3×10⁴ cells/well) alone or pulsed with individual peptide (10 μg/mL), or with the peptide pool (Peptide mix). The number of cells producing interferon-γ was then assessed by ELISPOT and is expressed as mean number of spot-forming cells (SFC) per million cells calculated in the case of peptide-stimulated T-cells minus the SFC obtained in the case of unstimulated cells. *The 111–125 ADAMTS13-derived peptide is used as a negative control, without detectable binding to HLA-DRB1*11:01 (data not shown).